The Vertiva™ On-Body Delivery System: Expanding Opportunities In Home-Based Care

By Dr. Adam Stops, Head of Product Management for Drug Delivery Systems, Stevanato Group

Sitting at the intersection of many trends currently shaping the future of healthcare, on-body delivery systems (OBDSs) can be seen as a breakthrough area in drug delivery. A fundamental advantage of OBDSs is that they offer patients the ability to self-administer therapies in their own homes. This fits with the recognised global shift in the delivery of care away from hospital or clinic settings in cases where the therapy being administered, and the delivery method, allow. This shift has many benefits for patients, not least because their lives are less disrupted by enforced travel, but also because they are able to retain a greater sense of control and agency over their own health.

Therapies that might have been delivered intravenously at a hospital under the supervision of an HCP will need to undergo a reformulation process to make them suitable for patient-led delivery via a prefilled syringe, autoinjector or OBDS. However, particularly in the case of biologics, this can result in highly concentrated drugs with high viscosity or formulations that must be delivered in high volumes. In light of this, OBDSs have the distinct benefit of being able to deliver volumes of between 3 mL and 10 mL, and potentially more.

In this article, Adam Stops, PhD, Head of Product Management for Drug Delivery Systems at Stevanato Group, introduces Vertiva™, the company’s next-generation on-body delivery system platform, and discusses how it meets the needs of pharma companies looking to deliver large-volume doses in a patient-centric manner.